secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sagimet Biosciences Inc. (SGMT)
CIK:        0001400118
Form:       8-K/A
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0001104659-24-071014
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sagimet reports positive Phase 2b MASH data for denifanstat; primary endpoints met
--------------------------------------------------------------------------------

- Primary endpoints achieved: ≥2-point NAS reduction without fibrosis worsening (38% vs 16%, p=0.0035) and MASH resolution (26% vs 11%, p=0.0173) in ITT.
- Fibrosis improvement ≥1 stage without MASH worsening: ITT 30% vs 14% (p=0.0199); F3 subgroup 49% vs 13% (p=0.0032).
- Fibrosis improvement ≥2 stages: mITT 20% vs 2% (p=0.0065); F3 34% vs 4% (p=0.0050).
- No treatment-related SAEs; discontinuation rate 19.6% denifanstat vs 5.4% placebo.
- Company plans to initiate Phase 3 registrational program for denifanstat in MASH in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1400118/000110465924071014/0001104659-24-071014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1400118/000110465924071014/tm2417159d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-071014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer